Physician profile
Roy R Brown
NPI 1417990565
$4,386.02
in general payments reported to CMS, 2019-2025
29 companies · $1,675 in 2025
The $1,675 reported for 2025 was more than what 76% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $824 · 2020: $135 · 2021: $378 · 2022: $499 · 2023: $820 · 2024: $53.63 · 2025: $1,675.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,478 · Travel and Lodging: $1,071.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,478.11 |
| Travel and Lodging | $1,071.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,484.96 | 2022-2025 | Altaviva, Interstim |
| Boston Scientific Corporation | $857.42 | 2019-2025 | Lithovue, Lumenis Pulse 120h, Rezum Generator |
| Axonics, INC. | $295.10 | 2021-2022 | |
| Astellas Pharma US INC | $231.90 | 2019-2021 | |
| Dornier Medtech America, INC | $170.83 | 2025 | Dornier Medtech |
| Olympus America INC. | $149.21 | 2023 | Itind System |
| Procept Biorobotics Corporation | $147.18 | 2023 | Aquabeam Robotic System |
| Teleflex LLC | $135.53 | 2022 | |
| Medtronic USA, INC. | $122.30 | 2019-2020 | |
| Intuitive Surgical, INC. | $108.29 | 2019 | |
| Dendreon Pharmaceuticals LLC | $104.06 | 2019-2021 | |
| Myriad Genetic Laboratories, INC. | $82.10 | 2023-2025 | Prolaris, Myrisk |
| Coloplast Corp | $74.75 | 2019-2024 | |
| Lumenis, INC | $72.62 | 2021 | |
| Janssen Biotech, INC. | $43.87 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $35.63 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $32.88 | 2025 | Gemtesa |
| Tolmar Pharmaceuticals, INC. | $30.74 | 2019 | |
| Endo Pharmaceuticals INC. | $30.50 | 2019 | |
| Abbvie INC. | $29.55 | 2022 | |
| C. R. Bard, INC. & Subsidiaries | $27.22 | 2021 | |
| 180 Medical, INC. | $27.18 | 2019-2021 | |
| Baxter Healthcare | $20.19 | 2025 | Perclot |
| Pacira Pharmaceuticals Incorporated | $16.76 | 2019 | |
| Tolmar, INC. | $16.48 | 2025 | Jatenzo |
| Verity Pharmaceuticals INC. | $15.77 | 2023 | Trelstar |
| Amgen INC. | $11.65 | 2019 | |
| Allergan, INC. | $11.35 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$986.22 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.